Create an Account
  1. Home
  2. Specialty
  3. General Ophthalmology

Mapping Out a Strategy: Diagnostic Tools and Possible Therapies for Geographic Atrophy

Mapping Out a Strategy Diagnostic Tools and Possible Therapies for Geographic Atrophy
Media formats available:
Details
Presenters

  • Overview

    Clinicians who evaluate patients for geographic atrophy (GA) face a daunting challenge. Although there are no approved therapies for the treatment of GA, there are numerous candidates at various stages of development. Keeping track of them all is a tall order. Drs. Sadda, Modi, and Baumal discuss these potential therapies as well as risk factors that drive this disease, imaging modalities that are best suited for GA evaluation, and the type of lesion patterns that place patients at high risk for progression. 

    This activity is supported by an unrestricted medical educational grant from Apellis Pharmaceuticals.

     

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Summarize the prevalence of AMD and GA and define the burden of illness linked specifically to GA
    • Comprehend and explain the pathogenesis of GA
    • Describe GA disease detection and factors influencing progression
    • Appraise the therapies targeting GA that have been explored as well as those in the pipeline

    • Accreditation

      Sponsored by:  
      Evolve Medical Education LLC (Evolve) is a COPE-Accredited Administrator. 
      This activity, COPE Activity Number 124958, is accredited by COPE for continuing education for optometrists.This course is approved for 1.25 hours of CE.

      Course #: 81554-TD
      Activity #: 124958

      COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.

      Provided by Evolve Medical Education 

      Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
      Evolve designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      SriniVas Sadda, MD

      SriniVas Sadda, MD

      Professor of Ophthalmology

      Doheny Eye Institute, UCLA

      Los Angeles, CA


      Yasha S. Modi, MD

      Yasha S. Modi, MD

      Associate Professor of Ophthalmology

      Department of Ophthalmology

      Director of Tele-Retina NYU Langone Health

      New York, NY


      Caroline R. Baumal, MD

      Caroline R. Baumal, MD

      Professor of Ophthalmology
      New England Eye Center
      Tufts University School of Medicine
      Boston, MA


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      SriniVas Sadda, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alexion, Allergan, Alnylam, Amgen, Apellis Pharmaceuticals, Astellas, Bayer, Biogen, Catalyst Pharma, CenterVue, Genentech/Roche, Heidelberg, Inozyme, Iveric Bio, Notal, Novartis, Oculis, Optos, Oyster Point Pharma, Pfizer, Regeneron, and Thrombogenics/Oxurion. Grant/Research Support: Carl Zeiss Meditec. Research Instruments: Carl Zeiss Meditec, CenterVue, Heidelberg, Nidek, Optos, and Topcon. Speaker's Bureau: Nidek, Novartis, Optos, and Thrombogenics/Oxurion.

      Yasha S. Modi, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Allergan/AbbVie, Carl Zeiss Meditec, DORC, Genentech, Iveric Bio, and Théa Pharma.

      Caroline R. Baumal, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Apellis, Genentech, Novartis, and Ora. Speaker's Bureau: Carl Zeiss Meditic and Regeneron Pharmaceuticals. 

      The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Apellis Pharmaceuticals. 

      This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Register

      We're glad to see you're enjoying Evolve Medical Education…
      but how about a more personalized experience?

      Register for free